"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t done.

Robert F. Kennedy Jr. has pledged to tackle high rates of chronic diseases such as diabetes and obesity as President-elect ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

During the SELECT trial, almost 30 percent of individuals stopped using semaglutide, but "real-world estimates" of GLP-1 RA ...

GLP-1 agonist drugs like Ozempic, and SLGT2 inhibitor drugs like Jardiance have been linked with a lower risk of a second ...

As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...